NCT06489249 Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
| NCT ID | NCT06489249 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Iowa |
| Condition | Electronic Cigarette Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2024-08-15 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2024-08-15 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
Eligibility Criteria
Inclusion Criteria: * 18 - 24 years of age * no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use). Exclusion Criteria: * tobacco cigarette use (current or history of) * use of stimulant drugs * skin diseases * cardiovascular disease * diagnosed or suspected hepatic or metabolic disease including diabetes * statin or other cholesterol-lowering medication * antihypertensive medication * current pregnancy or breastfeeding * blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic * allergy to materials used during the experiment * known allergies to salsalate or other study drugs
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06489249 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 24 Years, studying Electronic Cigarette Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06489249 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06489249 currently recruiting?
Yes, NCT06489249 is actively recruiting participants. Contact the research team at anna-stanhewicz@uiowa.edu for enrollment information.
Where is the NCT06489249 trial being conducted?
This trial is being conducted at Iowa City, United States, Iowa City, United States.
Who is sponsoring the NCT06489249 clinical trial?
NCT06489249 is sponsored by University of Iowa. The trial plans to enroll 24 participants.